OpenBilldrug price receipt

NADAC week of 2026-10-14

LAMIVUDINE 10 MG/ML ORAL SOLN

For 240 mL

Pharmacies pay

$52.23 filed

240 × $0.21763 per ML

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-22 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.


The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$65.06 estimated

$52.23 + $7.83 (15%) + $5.00 fee per fill = $65.06

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-07-22 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

LAMIVUDINE 10 MG/ML ORAL SOLN is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “lamivudine” and “lamivudine oral”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as solution and its route as oral.

Its labelers, the companies named on the label, are Rising Pharma Holdings, Inc., Chartwell RX, LLC and Aurobindo Pharma Limited.

FDA lists it under 2 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 4 NDCs (National Drug Codes); the FDA directory lists 3 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $52.23 for 240 mL (240 × $0.21763 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-07-22. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

The NADAC of all 4 NDCs was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: those prices took effect on 2026-07-22. The file is new; the price is not.

All 4 NDCs

Other strengths, forms and brands

3 other products in the NADAC file share an FDA nonproprietary name with LAMIVUDINE 10 MG/ML ORAL SOLN.

ProductPharmacies pay per unitMedicare per unit
LAMIVUDINE 10 MG/ML ORAL SOLN this page
generic · solution
$0.21763 per ML filed
eff. 2026-07-22
We don’t know yet
LAMIVUDINE 150 MG TABLET
generic · tablet, film coated
$0.48868 per EA filed
eff. 2026-09-23
We don’t know yet
LAMIVUDINE 300 MG TABLET
generic · tablet, film coated
$1.40117 per EA filed
eff. 2026-09-23
We don’t know yet
LAMIVUDINE HBV 100 MG TABLET
generic · tablet, film coated
$9.47647 per EA filed
eff. 2026-09-23
We don’t know yet

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

We don’t know yet; the card above says why.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why does this page start at 240 mL?
NADAC prices this product per ML. The FDA NDC Directory’s package description gives 240 mL in one package for the 3 of this product’s 4 NDCs it lists (“240 mL in 1 BOTTLE (57237-274-24)”), so the card starts at one package: 240 ML. Change it to match your prescription.